Co-Authors
This is a "connection" page, showing publications co-authored by Bruno Canard and Jean-Claude Guillemot.
Connection Strength
0.852
-
A fluorescence-based high throughput-screening assay for the SARS-CoV RNA synthesis complex. J Virol Methods. 2021 02; 288:114013.
Score: 0.228
-
Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020 06; 178:104793.
Score: 0.219
-
The SARS-Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein. Virus Res. 2008 May; 133(2):136-48.
Score: 0.094
-
A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus. EMBO J. 2006 Oct 18; 25(20):4933-42.
Score: 0.086
-
Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. ACS Cent Sci. 2021 May 26; 7(5):792-802.
Score: 0.059
-
Drugs against SARS-CoV-2: What do we know about their mode of action? Rev Med Virol. 2020 11; 30(6):1-10.
Score: 0.056
-
Toward the identification of viral cap-methyltransferase inhibitors by fluorescence screening assay. Antiviral Res. 2017 08; 144:330-339.
Score: 0.045
-
Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. J Biol Chem. 2014 Sep 12; 289(37):25783-96.
Score: 0.037
-
Molecular mapping of the RNA Cap 2'-O-methyltransferase activation interface between severe acute respiratory syndrome coronavirus nsp10 and nsp16. J Biol Chem. 2010 Oct 22; 285(43):33230-33241.
Score: 0.028